Tumor neoantigen specific T cells will be infused intravenously into patients. The number of T cells will be more than 1.0E9.

Isolate the patient's autologous monocytes, induce and culture them into tumor antigen presenting cells in vitro, and then phagocytose tumor tissue cells obtained from biopsy or surgery to present tumor neoantigens to autologous T cells. The final product For tumor neoantigen specific T cells (NeoT).

tumor neoantigen specific T cell

Jiang Longwei, Master

Jia Shaochang, MD

Zen Ke, PhD

Liu Yuan, PhD

The goal of this clinical trial is to learn if tumor neoantigen-specific T cells can treat patients with advanced solid tumors. The main questions it aims to answer are:

Evaluate the safety of intravenous infusion of tumor neoantigen-specific T cells in the treatment of advanced solid tumors such as ovarian cancer, non-small cell lung cancer, and colorectal cancer.

To evaluate the effectiveness of intravenous infusion of tumor neoantigen-specific T cells in the treatment of advanced solid tumors such as ovarian cancer, non-small cell lung cancer, and colorectal cancer and to study its immunological properties in patients.

In this open, single-armed study, selected patients with advanced solid tumor confirmed by Histopathology will be received tumor neoantigen specific T cells treatment. First, their tumor specimen will be collected from surgery or puncture，then their PBMC will be separated by blood cell separator. This cells will be cultured and selected in GMP laboratory to make tumor neoantigen specific T cells. The tumor neoantigen specific T cells will be infused intravenous into patients.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors	NCT06431529	Tumor, Solid	tumor neoantige...	18 Years - 75 Years	Jinling Hospital, China
A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors	NCT06431529	Tumor, Solid	tumor neoantige...	18 Years - 75 Years	Jinling Hospital, China
A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors	NCT06431529	Tumor, Solid	tumor neoantige...	18 Years - 75 Years	Jinling Hospital, China

Spots Global Cancer Trial Database for tumor neoantigen specific t cell